News

Barriers seen in accessing specialty care for CF patients: Study

For people with cystic fibrosis (CF), key barriers to getting specialty care include concerns about addiction and affordability, according to a new survey of clinicians. In fact, more than one-third of respondents cited difficulties for CF patients in accessing specialists and issues with insurance and treatment costs. “In this…

Kaftrio effective in CF patients with advanced lung disease: Study

Kaftrio (elexacaftor, tezacaftor, and ivacaftor) safely and effectively eases structural lung damage and improves lung function and the quality of life for people with cystic fibrosis (CF) who have advanced lung disease. That’s according to data from a compassionate use program in the Netherlands that let patients with severely…

Trikafta led to greater drop in lung exacerbations in men than women

Men with cystic fibrosis (CF) saw greater reductions in lung symptom exacerbations after starting treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) than their female counterparts, according to a recent study. Changes in nutritional status, lung infections, and lung function were similar between the sexes. The findings overall suggest that high-efficacy therapies…

Inhaled TAVT-135 shows promise as treatment for all CF types

TAVT-135, an inhaled treatment candidate being developed for people with cystic fibrosis (CF) regardless of their underlying mutation type, was found to help normalize mucus production in a cell model of the disease. According to researchers from Tavanta Therapeutics, the treatment’s developer, the findings of their in vitro…

Scientists in NYC aim to increase diversity in CF clinical trials

Scientists in New York are calling on the cystic fibrosis (CF) research community to take proactive steps to increase diversity in clinical trials — which now typically include a disproportionate number of non-Hispanic white people, and fewer patients from other racial and ethnic backgrounds. “Ensuring that pwCF [people with…

Patients with mental health issues benefit from lower Kaftrio dose

Reducing the dose of Kaftrio (elexacaftor, tezacaftor, and ivacaftor) should be considered for cystic fibrosis (CF) patients who report cognitive and psychological side effects, a study in Ireland suggests. Such patients should have an individualized dosage to minimize side effects while maintaining CFTR modulator therapy. “Dose reduction…